Dr. Durcan, et al reply

REFERENCES

1. 1.↵
   1. Weinlander E,
   2. Ringeisen AL,
   3. Mititelu M

   . Retinopathy in the era of routine hydroxychloroquine monitoring. J Rheumatol 2016;43:1254–5.

   OpenUrlFREE Full Text
2. 2.↵
   1. Durcan L,
   2. Clarke WA,
   3. Magder LS,
   4. Petri M

   . Hydroxychloroquine blood levels in systemic lupus erythematosus: clarifying dosing controversies and improving adherence. J Rheumatol 2015;42:2092–7.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Melles RB,
   2. Marmor MF

   . The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol 2014;132:1453–60.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Alarcón GS,
   2. McGwin G,
   3. Bertoli AM,
   4. Fessler BJ,
   5. Calvo-Alén J,
   6. Bastian HM,
   7. et al;
   8. LUMINA Study Group

   . Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 2007;66:1168–72.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Kasitanon N,
   2. Magder LS,
   3. Petri M

   . Predictors of survival in systemic lupus erythematosus. Medicine 2006;85:147–56.

   OpenUrlCrossRefPubMed